Investment Thesis
Lipella Pharmaceuticals faces imminent liquidity crisis with only ~5-6 months of cash runway at current burn rates ($3.8-4.0M annually) against minimal cash reserves of $1.9M. Despite 19.3% YoY revenue growth, the company remains pre-commercial with $216K in revenue against $4.0M in operating losses, demonstrating no viable path to profitability without significant capital infusion.
Strengths
- Positive revenue growth trajectory (+19.3% YoY)
- Solid current ratio of 3.24x provides near-term liquidity cushion
- Minimal debt burden with 0.00x debt-to-equity ratio
Risks
- Critical cash runway of only 5-6 months at current operating burn rate
- Massive operating losses ($4.0M) relative to negligible revenue ($216K)
- Pre-commercial stage with no approved revenue-generating products evident
- Deeply negative profitability metrics (Operating Margin -1831.7%, Net Margin -1799.1%)
- Going concern risk without near-term financing or major business inflection
Key Metrics to Watch
- Cash burn rate and remaining runway
- Revenue monetization and clinical trial progress
- Equity financing announcements or partnerships
Financial Metrics
Revenue
216.1K
Net Income
-3.9M
EPS (Diluted)
$-1.07
Free Cash Flow
-3.8M
Total Assets
2.3M
Cash
1.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,831.7%
Net Margin
-1,799.1%
ROE
-261.4%
ROA
-165.5%
FCF Margin
-1,758.2%
Balance Sheet & Liquidity
Current Ratio
3.24x
Quick Ratio
3.24x
Debt/Equity
0.00x
Debt/Assets
36.7%
Interest Coverage
-364.92x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-12T15:42:21.008852 |
Data as of: 2025-09-30 |
Powered by Claude AI